Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.

D'Haens, Geert; Kelly, Orlaith; Battat, Robert; Silverberg, Mark S.; Laharie, David; Louis, Edouard; Savarino, Edoardo; Bodini, Giorgia; Yarur, Andres; Boland, Brigid S.; Afif, Waqqas; Li, Xiao-Jun; Hale, Michael; Ho, Jessica; Kondragunta, Venkateswarlu; Huang, Benjamin; Kuy, Crystal; Okada, Lauren; Hester, Kelly D.; Bray, Kurtis R.; Mimms, Larry; Jain, Anjali; Singh, Siddharth; Collins, Angelina; Valasek, Mark A.; Sandborn, William J.; Vermeire, Severine; Dulai, Parambir S.

doi:10.1053/j.gastro.2019.10.034

Article (Scientific journals)

Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.

D'Haens, Geert; Kelly, Orlaith; Battat, Robert et al.

2019 • In Gastroenterology

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/247539

DOI
10.1053/j.gastro.2019.10.034

PubMed
31711925

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

7_Development and validation of test to monitor endoscopic... serum markers of mucosal healing in Crohn_Gastroenterology_PrePA.pdf

Author preprint (940.43 kB)

Download

Copyright (c) 2019 AGA Institute. Published by Elsevier Inc. All rights reserved. Copyright © 2020 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V. ScienceDirect ® is a registered trademark of Elsevier B.V.

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

IBD; Monitor; Resolution; Response to Treatment

Abstract :

[en] BACKGROUND & AIMS: Noninvasive tests to measure endoscopic activity in patients with Crohn's disease (CD) have limitations. We aimed to develop a test to identify patients in remission, based on endoscopic analysis, and monitor CD activity based on serum levels of proteins. METHODS: We developed a test to measure 13 proteins in blood (ANG1, ANG2, CRP, SAA1, IL7, EMMPRIN, MMP1, MMP2, MMP3, MMP9, TGFA, CEACAM1, and VCAM1), called the endoscopic healing index [EHI], using samples from 278 patients with CD from a multinational training cohort. We validated the test using 2 independent cohorts of patients with CD: 116 biologic-naive patients with early-stage CD (validation cohort 1) and 195 biologic-exposed patients with chronic CD (validation cohort 2). The ability of the test to identify patients with active disease vs patients in remission (defined as a simple endoscopic score for CD of </=2 and </=1 in each segment, or a total CD endoscopic index of severity score <3) was assessed by using area under receiver operating characteristic curve (AUROC) analysis. The diagnostic accuracy of the test was compared with that of measurement of serum C-reactive protein (CRP) and fecal calprotectin. RESULTS: The EHI scores range from 0 to 100 units; higher scores indicate more severe CD activity, based on endoscopy findings. The EHI identified patients in remission with an AUROC of 0.962 in validation cohort 1 (95% confidence interval, 0.942-0.982) and an AUROC of 0.693 in validation cohort 2 (95% confidence interval, 0.619-0.767), regardless of CD location or phenotype. A cutoff value of 20 points identified patients in remission with the highest level of sensitivity (97.1% in validation cohort 1 and 83.2% in validation cohort 2), with specificity values of 69.0% and 36.6%, respectively. A cutoff value of 50 points identified patients in remission with the highest level of specificity (100% in validation cohort 1 and 87.8% in validation cohort 2), with sensitivity values of 37.3% and 30.0%, respectively. The EHI identified patients in remission with a significantly higher AUROC value than the test for CRP (0.876, P < .001 in validation cohort 1 and 0.624, P = .109 in validation cohort 2). In analysis of patients with available FC measurements, the AUROC value for the EHI did not differ significantly from that of measurement of FC (AUROC, 0.950 for EHI vs AUROC, 0.923 for FC; P = .147 in validation cohort 1 and AUROC, 0.803 for EHI vs AUROC, 0.854 for FC; P = .298 in validation cohort 2). CONCLUSIONS: We developed an index called the EHI to identify patients with CD in endoscopic remission based on blood levels of 13 proteins. The EHI identified patients with resolution of endoscopic disease activity, with good overall accuracy, although with variation between the 2 cohorts assessed. The EHI AUROC values were comparable to measurement of FC and higher than measurement of serum CRP. The test might be used in practice to assess endoscopic activity in patients with CD.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

D'Haens, Geert

Kelly, Orlaith

Battat, Robert

Silverberg, Mark S.

Laharie, David

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Savarino, Edoardo

Bodini, Giorgia

Yarur, Andres

Boland, Brigid S.

More authors (18 more)

Language :

English

Title :

Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.

Publication date :

2019

Journal title :

Gastroenterology

ISSN :

0016-5085

eISSN :

1528-0012

Publisher :

Elsevier

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.sciencedirect.com/science/article/pii/S0016508519415254?via%3Dihub

Commentary :

Available on ORBi :

since 19 May 2020

Statistics

Number of views

123 (3 by ULiège)

Number of downloads

74 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Peyrin-Biroulet, L., Loftus, E.V. Jr., Colombel, J.F., et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 105 (2010), 289–297.
Baert, F., Moortgat, L., Van Assche, G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138 (2010), 463–468.
Froslie, K.F., Jahnsen, J., Moum, B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133 (2007), 412–422.
af Björkesten, C.G., Nieminen, U., Sipponen, T., et al. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 48 (2013), 543–551.
Shah, S.C., Colombel, J.F., Sands, B.E., et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther 43 (2016), 317–333.
Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
Bouguen, G., Levesque, B.G., Feagan, B.G., et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol 13 (2015), 1042–1050.
Bouguen, G., Levesque, B.G., Pola, S., et al. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol 12 (2014), 978–985.
Buisson, A., Gonzalez, F., Poullenot, F., et al. Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease. Inflamm Bowel Dis 23 (2017), 1425–1433.
Limketkai, B.N., Singh, S., Jairath, V., et al. US practice patterns and impact of monitoring for mucosal inflammation after biologic initiation in inflammatory bowel disease. Inflamm Bowel Dis 25 (2019), 1828–1837.
Colombel, J.F., Panaccione, R., Bossuyt, P., et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390:10114 (2018), 2779–2789.
Lin, J.F., Chen, J.M., Zuo, J.H., et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 20 (2014), 1407–1415.
Mosli, M.H., Zou, G., Garg, S.K., et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 110 (2015), 802–819.
van Deen, W.K., van Oijen, M.G., Myers, K.D., et al. A nationwide 2010–2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis 20 (2014), 1747–1753.
Pepe, M.S., Feng, Z., Janes, H., et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100 (2008), 1432–1438.
Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ, 351, 2015, h5527.
Louis, E., Mary, J.Y., Vernier-Massouille, G., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142 (2012), 63–70.
D'Haens, G., Vermeire, S., Lambrecht, G., et al. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn's disease. Gastroenterology 154 (2018), 1343–1351.
Dulai, P.S., Levesque, B.G., Feagan, B.G., et al. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc 82 (2015), 246–255.
Daperno, M., D'Haens, G., Van Assche, G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 60 (2004), 505–512.
Mary, J.Y., Modigliani, R., Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30 (1989), 983–989.
Padoan, A., D'Inca, R., Scapellato, M.L., et al. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clin Chem Lab Med 56 (2018), 1926–1935.
DeLong, E.R., DeLong, D.M., Clarke-Pearson, D.L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988), 837–845.
Simel, D.L., Samsa, G.P., Matchar, D.B., Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 44 (1991), 763–770.
Cohen, J., Statistical power analysis for the behavioral sciences. 2nd ed., 1988, Lawrence Erlbaum, Mahwah, NJ.
Heida, A., Knol, M., Kobold, A.M., et al. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol 15 (2017), 1742–1749.
Yarur, A.J., Quintero, M.A., Jain, A., et al. Serum amyloid A as a surrogate marker for mucosal and histologic inflammation in patients with Crohn's disease. Inflamm Bowel Dis 23 (2017), 158–164.
de Bruyn, J.R., van den Brink, G.R., Steenkamer, J., et al. Fibrostenotic phenotype of myofibroblasts in Crohn's disease is dependent on tissue stiffness and reversed by LOX inhibition. J Crohns Colitis 12 (2018), 849–859.
Baugh, M.D., Perry, M.J., Hollander, A.P., et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117 (1999), 814–822.
Faubion, W.A. Jr., Fletcher, J.G., O'Byrne, S., et al. EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol 108 (2013), 1891–1900.
Schreiber, S., Siegel, C.A., Friedenberg, K.A., et al. A phase 2, randomized, placebo-controlled study evaluating matrix metalloproteinase-9 inhibitor, andecaliximab, in patients with moderately to severely active Crohn's disease. J Crohns Colitis 12 (2018), 1014–1020.
Kumar, D., Vetrivel, U., Parameswaran, S., et al. Structural insights on druggable hotspots in CD147: a bull's eye view. Life Sci 224 (2019), 76–87.
Till, A., Rosenstiel, P., Brautigam, K., et al. A role for membrane-bound CD147 in NOD2-mediated recognition of bacterial cytoinvasion. J Cell Sci 121 (2008), 487–495.
Zaiss, D.M.W., Gause, W.C., Osborne, L.C., et al. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity 42 (2015), 216–226.
Algaba, A., Linares, P.M., Encarnacion Fernandez-Contreras, M., et al. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients. Inflamm Bowel Dis 20 (2014), 695–702.
Linares, P.M., Chaparro, M., Gisbert, J.P., Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. J Crohns Colitis 8 (2014), 183–190.
Martin, C.E., Spasova, D.S., Frimpong-Boateng, K., et al. Interleukin-7 availability is maintained by a hematopoietic cytokine sink comprising innate lymphoid cells and T cells. Immunity 47 (2017), 171–182.
Zundler, S., Fischer, A., Schillinger, D., et al. The α4β1 homing pathway is essential for ileal homing of Crohn's disease effector T cells in vivo. Inflamm Bowel Dis 23 (2017), 379–391.
Kalla, R., Kennedy, N.A., Ventham, N.T., et al. Serum calprotectin: a novel diagnostic and prognostic marker in inflammatory bowel diseases. Am J Gastroenterol 111 (2016), 1796–1805.
Gecse, K.B., Brandse, J.F., van Wilpe, S., et al. Impact of disease location on fecal calprotectin levels in Crohn's disease. Scand J Gastroenterol 50 (2015), 841–847.
Stevens, T., D'Haens, G.R., Buskens, C.J., et al. P150. Low diagnostic accuracy of faecal calprotectin to predict mucosal inflammation in Crohn's disease patients with active perianal fistulas. Abstract presented at: European Crohn's and Colitis Organization Congress, 2018 Vienna, Austria.
Whitehead, S.J., French, J., Brookes, M.J., et al. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 50 (2013), 53–61.
Oyaert, M., Boel, A., Jacobs, J., et al. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med 55 (2017), 1564–1573.
Rodriguez, A., Yokomizo, L., Christofferson, M., et al. Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. World J Gastrointest Pharmacol Ther 8 (2017), 127–130.
Hejl, J., Theede, K., Mollgren, B., et al. Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Pract Lab Med 10 (2018), 10–14.
Whitehead, S.J., Ford, C., Gama, R.M., et al. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12. J Clin Pathol 70 (2017), 1049–1056.
Jang, H.W., Kim, H.S., Park, S.J., et al. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease. Intest Res 14 (2016), 305–313.
Wright, E.K., Kamm, M.A., De Cruz, P., et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology 148 (2015), 938–947.